GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement
GT Biopharma (NASDAQ: GTBP), a clinical stage immuno-oncology company developing therapeutics based on their proprietary TriKE® natural killer (NK) cell engager platform, has filed a Request for Withdrawal with the SEC regarding their Form S-1 Registration Statement (File No. 333-284032).
The Registration Statement, originally filed on December 23, 2024, had not been declared effective by the SEC, and no securities were sold in connection with the offering described in the document. The company clarified that this announcement does not constitute an offer to sell or solicitation to buy the Company's common stock or any securities.
GT Biopharma further emphasized that no offer, solicitation, or sale of securities mentioned would occur in any state or jurisdiction where such actions would be unlawful prior to proper registration or qualification under applicable securities laws.
GT Biopharma (NASDAQ: GTBP), un'azienda di immuno-oncologia in fase clinica che sviluppa terapie basate sulla propria piattaforma proprietaria di TriKE® natural killer (NK) cell engager, ha presentato una Richiesta di Ritiro presso la SEC riguardo al loro Modulo S-1 di Dichiarazione di Registrazione (File No. 333-284032).
La Dichiarazione di Registrazione, originariamente presentata il 23 dicembre 2024, non era stata dichiarata efficace dalla SEC e non sono stati venduti titoli in relazione all'offerta descritta nel documento. L'azienda ha chiarito che questo annuncio non costituisce un'offerta di vendita né una sollecitazione all'acquisto delle azioni ordinarie della Società o di qualsiasi titolo.
GT Biopharma ha ulteriormente sottolineato che non vi sarà alcuna offerta, sollecitazione o vendita di titoli menzionati in alcuno stato o giurisdizione in cui tali azioni sarebbero illegali prima di una corretta registrazione o qualificazione ai sensi delle leggi sui titoli applicabili.
GT Biopharma (NASDAQ: GTBP), una empresa de inmuno-oncología en etapa clínica que desarrolla terapias basadas en su plataforma propietaria de TriKE® natural killer (NK) cell engager, ha presentado una Solicitud de Retiro ante la SEC respecto a su Declaración de Registro del Formulario S-1 (File No. 333-284032).
La Declaración de Registro, presentada originalmente el 23 de diciembre de 2024, no había sido declarada efectiva por la SEC y no se vendieron valores en relación con la oferta descrita en el documento. La empresa aclaró que este anuncio no constituye una oferta de venta ni una solicitud de compra de las acciones ordinarias de la Compañía o de ningún valor.
GT Biopharma enfatizó además que no habrá ninguna oferta, solicitud o venta de valores mencionados en ningún estado o jurisdicción donde tales acciones serían ilegales antes de la debida registro o calificación bajo las leyes de valores aplicables.
GT Biopharma (NASDAQ: GTBP)는 독자적인 TriKE® 자연 살해 세포(NK) 결합제 플랫폼을 기반으로 치료제를 개발하는 임상 단계의 면역 종양학 회사로, SEC에 그들의 S-1 등록 명세서(파일 번호: 333-284032)와 관련하여 철회 요청을 제출했습니다.
등록 명세서는 원래 2024년 12월 23일에 제출되었으며 SEC에 의해 효력이 발생하지 않았고, 해당 문서에 설명된 제안과 관련하여 증권이 판매되지 않았습니다. 회사는 이 발표가 회사의 보통주 또는 기타 증권을 판매하겠다는 제안이나 구매 요청이 아님을 명확히 했습니다.
GT Biopharma는 또한 언급된 증권의 제안, 요청 또는 판매가 적절한 등록 또는 관련 증권 법률에 따른 자격이 없는 주 또는 관할권에서 발생하지 않을 것이라고 강조했습니다.
GT Biopharma (NASDAQ: GTBP), une entreprise d'immuno-oncologie en phase clinique développant des thérapies basées sur sa plateforme propriétaire de TriKE® natural killer (NK) cell engager, a déposé une Demande de Retrait auprès de la SEC concernant sa Déclaration d'Enregistrement Formulaire S-1 (Numéro de fichier 333-284032).
La Déclaration d'Enregistrement, initialement déposée le 23 décembre 2024, n'avait pas été déclarée effective par la SEC et aucun titre n'a été vendu en lien avec l'offre décrite dans le document. L'entreprise a précisé que cette annonce ne constitue pas une offre de vente ni une sollicitation d'achat des actions ordinaires de la Société ou de tout autre titre.
GT Biopharma a également souligné qu'aucune offre, sollicitation ou vente des titres mentionnés n'aurait lieu dans un État ou une juridiction où de telles actions seraient illégales avant une inscription ou qualification appropriée conformément aux lois sur les valeurs mobilières applicables.
GT Biopharma (NASDAQ: GTBP), ein Unternehmen für Immunonkologie in der klinischen Phase, das Therapien auf der Grundlage seiner proprietären TriKE® natural killer (NK) cell engager Plattform entwickelt, hat einen Rückzugsantrag bei der SEC bezüglich ihrer S-1 Registrierungsanmeldung (Dateinummer 333-284032) eingereicht.
Die Registrierungsanmeldung, die ursprünglich am 23. Dezember 2024 eingereicht wurde, war von der SEC nicht für wirksam erklärt worden, und es wurden keine Wertpapiere verkauft im Zusammenhang mit dem in dem Dokument beschriebenen Angebot. Das Unternehmen stellte klar, dass diese Ankündigung kein Angebot zum Verkauf oder eine Aufforderung zum Kauf der Stammaktien des Unternehmens oder anderer Wertpapiere darstellt.
GT Biopharma betonte zudem, dass kein Angebot, keine Aufforderung oder kein Verkauf der genannten Wertpapiere in einem Bundesstaat oder einer Gerichtsbarkeit stattfinden wird, in der solche Handlungen vor einer ordnungsgemäßen Registrierung oder Qualifizierung nach den geltenden Wertpapiergesetzen rechtswidrig wären.
- None.
- Withdrawal of Registration Statement that could have raised capital
- Potential delay in funding opportunities
Insights
GT Biopharma's withdrawal of its S-1 registration statement represents a significant shift in the company's financing strategy that warrants investor attention. This development is particularly concerning given the company's precarious financial position, as evidenced by its micro-cap status with a market capitalization of just
The withdrawal of a registration statement filed only two months ago suggests an urgent reassessment of the company's capital raising approach. For clinical-stage biotechs, S-1 withdrawals typically indicate one of several scenarios: unfavorable market reception during testing-the-waters meetings with potential investors, feedback from the SEC requiring substantial revisions, or the emergence of alternative financing options that management deems more advantageous.
GT Biopharma's extremely low market capitalization raises serious concerns about its financial sustainability and NASDAQ listing status. NASDAQ's continued listing requirements generally include maintaining a minimum market value of listed securities of
The timing is particularly troubling for a company developing capital-intensive NK cell therapies. While the TriKE® platform shows promise in the competitive immuno-oncology landscape, advancing candidates through clinical trials requires substantial funding. Without successful financing, GT Biopharma may need to consider strategic alternatives such as:
- Pursuing private investments at potentially unfavorable terms
- Seeking development partnerships with larger pharmaceutical companies
- Downsizing operations or prioritizing only lead programs
- Exploring potential M&A opportunities as an exit strategy
Investors should closely monitor upcoming announcements regarding alternative financing plans, cash runway projections, and any changes to clinical development timelines. The company's next financial disclosure will be important in assessing its ability to sustain operations and advance its therapeutic pipeline without the capital that would have been raised through this now-withdrawn offering.
SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (“NK”) cell engager platform, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission (“SEC”) with respect to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-284032) that it filed with the SEC originally on December 23, 2024. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Company’s common stock or any securities, and there shall not be any offer, solicitation or sale of securities mentioned in the press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such any state or jurisdiction.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
FAQ
Why did GT Biopharma (GTBP) withdraw its S-1 Registration Statement?
When was GTBP's original S-1 Registration Statement filed?
Were any securities sold by GTBP before withdrawing the S-1?
What is GT Biopharma's (GTBP) main technology platform?
How might the S-1 withdrawal impact GTBP's financing strategy?
